A phase II study of @entity2727 for @entity308 in XXXX .

@entity1 @entity308 @entity5 @entity448 @entity1295 @entity2727
This study evaluated the use of @entity2727 for @entity308 in @entity5 DESIGN: Phase II open-label prospective study. ELIGIBILITY CRITERIA: No previous use of @entity2727 or current use of other antidepressants. EVALUATION: @entity308 and response to treatment were determined by asking the @entity1 : "are you depressed?" @entity1 were assessed at baseline and at days 3, 5, and 7. TREATMENT: Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days. RESPONSE CRITERIA: A negative response to the question: "are you depressed?" RESULTS: Some 41 @entity1 were enrolled and 30 (15 @entity1 , 15 @entity1 ) completed the study. Median age was 68 years (range: 30-90). @entity2727 was stopped for six @entity1 because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5, 29 maintained their positive response through day 7. @entity448 , @entity1295 , concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop. CONCLUSIONS: @entity2727 is effective for @entity308 in @entity5 A starting dose of 10 mg in divided doses is effective in most @entity1 . Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended.
